Select each profile to see why ZURZUVAE® (zuranolone) may be appropriate for these patient types.
These are hypothetical profiles only. All treatment decisions should be up to the discretion of the HCP and patient,
as each patient’s situation may vary.
Actor portrayals.
DSM-5-TR, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision; EPDS, Edinburgh Postnatal Depression Scale.
Patients must have 5 or more of the following symptoms nearly every day* during the same 2-week period and change from previous functioning. At least 1 symptom must either be depressed mood or loss of interest/pleasure.
*”Nearly every day” does not apply to weight gain and recurrent suicidal thoughts or actions or recurrent thoughts of death.
These are not the complete diagnostic criteria for PPD. The criteria listed here are adapted from the DSM-5-TR®. DSM-5® is a registered trademark of the American Psychiatric Association.
Take a novel approach to treating PPD
with a 14-day treatment1,2
Patients must have 5 or more of the following symptoms nearly every day* during the same 2-week period and change from previous functioning. At least 1 symptom must either be depressed mood or loss of interest/pleasure.
*”Nearly every day” does not apply to weight gain and recurrent suicidal thoughts or actions or recurrent thoughts of death.
These are not the complete diagnostic criteria for PPD. The criteria listed here are adapted from the DSM-5-TR®. DSM-5® is a registered trademark of the American Psychiatric Association.
Take a novel approach to treating PPD
with a 14-day treatment1,2
Patients must have 5 or more of the following symptoms nearly every day* during the same 2-week period and change from previous functioning. At least 1 symptom must either be depressed mood or loss of interest/pleasure.
*”Nearly every day” does not apply to weight gain and recurrent suicidal thoughts or actions or recurrent thoughts of death.
These are not the complete diagnostic criteria for PPD. The criteria listed here are adapted from the DSM-5-TR®. DSM-5® is a registered trademark of the American Psychiatric Association.
Take a novel approach to treating PPD
with a 14-day treatment1,2
References: 1. ZURZUVAE Prescribing Information. Cambridge, MA: Biogen and Sage Therapeutics, Inc. 2. Deligiannidis KM, Meltzer-Brody S, Maximos B, et al. Zuranolone for the Treatment of Postpartum Depression. Am J Psych. 2023;180(9):668-675. 3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed, Text Revision. American Psychiatric Publishing; 2022.